Loss of heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to chemotherapy response and outcome

Cancer Genetics and Cytogenetics

Volumn 123, Issue 2, 2000, Pages 109-113

  Sengelø, Lisa ^a   Christensen, Mariann ^b   Von Der Maase, Hans ^b   Horn, Thomas ^a   Marcussen, Niels ^b   Kamby, Claus ^a   Ørntoft, Torben ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MARKER; SATELLITE DNA;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; BLADDER CANCER; CHEMOTHERAPY; CHROMOSOME 10P; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 8P; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; ULTRASOUND; UROGENITAL TRACT TUMOR;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 8; DNA; FEMALE; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0034538363     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(00)00308-3     Document Type: Article

References (39)

1. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma; a cooperative group study
2. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
3. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract
4. Molecular alterations in bladder cancer
5. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer
6. A molecular model of human bladder cancer pathogenesis
7. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma
8. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma
9. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
10. Selective killing of cancer cells based on loss of heterozygosity and normal variation in the human genome; a new paradigm for anticancer drug therapy
11. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer
12. Localization of tumor suppressor gene associated with distant metastasis of urinary bladder cancer to a I-Mb interval on 8p22
13. Genetic alterations in primary bladder cancers and their metastases
14. Classification of bladder tumours based on the cellular pattern, preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years
15. Platinum analogue combination chemotherapy; cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors
16. Docetaxel (taxotere) and cisplatin in metastatic urothelial cancer; A phase II study
17. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy
18. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma; results and a report on prognostic factors in a medical research council study
19. Genetic basis of drug sensitivity in human testis tumor cells
20. Correlation of allelic loss of the P53 gene and tumor grade, stage, and malignant progression in bladder cancer
21. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas
22. Accumulated allelic losses in the development of invasive urothelial cancer
23. Allotype of human bladder cancer
24. Retinoblastoma gene mutations in primary human bladder cancer
25. Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer
26. Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer
27. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression
28. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer
29. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53
30. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinoma of the bladder
31. The relevance of p53 mutation in urological malignancies; possible clinical implications for bladder cancer
32. Prognostic value of P53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
33. p53 overexpression as a prognostic factor for advanced stage bladder cancer
34. Accumulation of nuclear p53 and tumor progression in bladder cancer
35. p53 mutations have no additional prognostic value over stage in bladder cancer
36. Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value
37. p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer
38. P53 and treatment of bladder cancer